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Introduction
Bacterial pathogens are masters of survival. They usually dis-
tinguish themselves from other strains within their species by 
a drastic change in lifestyle. Although closely related strains 
dwell in the soil or aqueous environments, pathogenic strains 
have evolved to thrive within a host. This brings the advan-
tage of a “niche” existence, but it also comes with many chal-
lenges. A pathogen must successfully infiltrate the host’s 
tissues by attaching to cells (sometimes entering them) and sub-
verting the cell’s natural functions for its own ends, all while 
avoiding the host’s immune system and other defenses. In the 
ongoing evolutionary arms race between pathogens and their 
hosts, pathogens tend to “think big,” generally targeting path-
ways that control important cellular functions like cytoskeletal 
dynamics (Haglund and Welch, 2011), initiation of cell death 
(Ashida et al., 2011), or autophagy and cellular membrane ho-
meostasis (Weinrauch and Zychlinsky, 1999; Bhavsar et al., 
2007; Alix et al., 2011; Ham et al., 2011). It is no wonder that 
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pathogens have evolved a large variety of tools to target one 
of the most ubiquitous of all eukaryotic signaling mechanisms: 
phosphorylation by protein kinases.
The human genome encodes 500 putative protein kinase 
genes, which correspond to 2% of all eukaryotic genes. This 
relatively small percentage of protein kinase–encoding genes is 
opposed by an enormous number of targets that are regulated by 
protein kinases. It has been estimated that roughly 30% of all 
cellular proteins may be modified by protein kinase activity 
(Manning et al., 2002). Consequently, kinases give rise to a vast 
network of interwoven signaling pathways, and the sheer com-
plexity of eukaryotic kinase signaling networks still baffles sci-
entists, biochemists, and system biologists alike. The field has 
made enormous progress toward understanding kinases on a 
biochemical and structural level by following specific “threads” 
of kinase regulatory cascades, starting from receptor activation 
to cellular consequences on the transcriptional level. However, 
in many cases, the field still lacks a deeper understanding about 
how seemingly “discrete” signaling pathways are communicat-
ing, thereby giving rise to a cellular fate that cannot be predicted 
based on additive outcomes of individual pathways.
An increasingly popular strategy to attempt to understand 
complex eukaryotic pathways is to study the mechanisms that 
pathogens use to subvert them. Invading pathogens specifically 
target signaling networks at a certain point, irreversibly provok-
ing the downstream event they require to meet their needs. To 
this end, the study of how bacterial pathogens manipulate com-
plex networks like the MAPK and nuclear factor B (NF-B) 
kinase pathways could illuminate otherwise inscrutable but im-
portant mechanisms of regulation and crosstalk in these path-
ways. Even a “simple” cascade can be regulated by diverse 
mechanisms, including dephosphorylation, binding to regula-
tors, subcellular localization, and degradation. We will describe 
examples of all of these regulatory principles, show how patho-
gens have taken advantage of them to achieve a dominating 
up- or down-regulation of kinase activity (Table I), and present 
insights that we have gained into the pathways themselves.
Bacterial pathogens use effector proteins to manipulate 
their hosts to propagate infection. These effectors divert 
host cell signaling pathways to the benefit of the pathogen 
and frequently target kinase signaling cascades. Notable 
pathways that are usurped include the nuclear factor B 
(NF-B), mitogen-activated protein kinase (MAPK), phos-
phatidylinositol 3-kinase (PI3K)/Akt, and p21-activated 
kinase (PAK) pathways. Analyzing the functions of patho-
genic effectors and their intersection with host kinase 
pathways has provided interesting insights into both the 
mechanisms of virulence and eukaryotic signaling.
Host–pathogen interactions
Manipulation of kinase signaling by  
bacterial pathogens
Anne Marie Krachler, Andrew R. Woolery, and Kim Orth
Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390
© 2011 Krachler et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after the pub-
lication date (see http://www.rupress.org/terms). After six months it is available under a 
Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, 
as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
T
H
E
J
O
U
R
N
A
L
O
F
C
E
L
L
B
IO
L
O
G
Y
 o
n
 N
ovem
ber 28, 2011
jcb.rupress.org
D
ow
nloaded from
 
Published November 28, 2011
JCB 2 of 10
mechanisms to counter the immune system, including disrup-
tion of immune recognition, inhibition of pro-inflammatory re-
sponses, or direct induction of immune cells (Fig. 1).
Activation of the NF-B and MAPK pathways results in a 
cascade of activated kinases that ultimately leads to a transcriptional 
response. For the MAPK signaling pathway, three types of kinases, 
herein referred to as MAP kinase kinase kinase (MKKK), MAP 
kinase kinase (MKK), and MAPK, are sequentially phosphory-
lated, ending with the phosphorylation of MAPK. The activated 
MAPK translocates to the nucleus to activate by phosphorylation 
proteins required for transcription of genes, including pro-
inflammatory signaling molecules (Zheng and Guan, 1994). The 
NF-B pathway is also activated by phosphorylation. In this case, 
it is activated by the IB kinase kinase (IKK) complex, which in 
turn phosphorylates the  subunit of inhibitor of NF-B (IB), the 
cytoplasmic binding partner of NF-B (Fig. 1). Phosphorylation 
of IB leads to its poly-ubiquitination and proteolytic degradation, 
resulting in exposure of the NLS on the now unbound NF-B 
(Alkalay et al., 1995). This promotes nuclear translocation of 
NF-B and transcriptional activation of genes containing a 
B site. Some NF-B–dependent genes require an additional 
Targeting of the NF-B and  
MAPK pathways
The evolution of eukaryotic immune recognition in the face 
of ever-changing bacterial phenotypes is a constant battle. The 
host’s innate immune system is poised to be triggered by signs 
of bacterial challenge, so-called pathogen-associated molecular 
patterns (PAMPs), which include characteristic molecules as-
sociated with infecting pathogens such as peptidoglycan, lipo-
polysaccharide, lipoteichoic acid, or flagellin (Lemaitre et al., 
1996; Medzhitov and Janeway, 2002). These are detected by 
eukaryotic pattern recognition receptors (PRRs), such as Toll-
like receptors (TLRs), and mannose receptors, or the family of 
cytoplasmic nucleotide-binding oligomerization domain con-
taining protein (NOD)-like receptors (NLRs; Medzhitov et al., 
1997; Inohara et al., 1999). When bound to their PAMP ligand, 
PRRs induce signaling cascades, most commonly NF-B and 
MAPK pathways, which in turn trigger pro-inflammatory re-
sponses such as the up-regulation of cytokines and antimicro-
bial peptides or activation of the complement cascade (Ruco et al., 
1978). For a recent review of innate immunity, please see 
Beutler (2009). However, pathogens have developed diverse 
Table I. Effectors manipulating host kinase signaling
Pathogen Effector Activity Host targets Pathway Phenotype Reference
P. gingivalis Fimbriae Binding CXCR4/ TLR2 NF-B inhibition Decreased ROS production Hajishengallis et al., 
2008
M. tuberculosis ? Binding CR-3 p38 MAPK activation Decreased CD1 expression Gagliardi et al., 2009
Shigella subspecies 
(ssp).
IpaH9.8 E3 ligase NEMO/ ABIN-1 NF-B inhibition Inhibition of pro-inflammatory 
responses
Ashida et al., 2010
Shigella ssp. OspG Kinase UbcH5 NF-B inhibition Inhibition of pro-inflammatory 
responses
Kim et al., 2005
Shigella ssp. OspF Phosphothreonine 
lyase
ERK1/2 ERK inhibition Inhibition of pro-inflammatory 
responses
Arbibe et al., 2007; 
Kramer et al., 2007;  
Li et al., 2007
Shigella ssp. OspE Binding Focal adhesions ILK activation Stabilization of intestinal lining Kim et al., 2009
A. salmonicida AopP Acetyltransferase ? NF-B inhibition Inhibition of pro-inflammatory 
responses
Fehr et al., 2006
V. parahaemolyticus VopA/P Acetyltransferase MKKs MAPK inhibition Growth arrest Trosky et al., 2007
EHEC EspG Binding ARFs/PAKs Arf inhibition/ 
PAK activation
Reprogramming of  
intracellular trafficking
Selyunin et al., 2011
EPEC/EHEC NleH Binding RPS3 partial NF-B  
inhibition
Increased bacterial coloniza-
tion, decreased mortality of host
Wan et al., 2011
EPEC NleE ? IKK NF-B inhibition Inhibition of pro-inflammatory 
responses
Nadler et al., 2010; 
Vossenkämper et al., 
2010
EPEC NleC/NleD Proteases RelA NF-B inhibition Inhibition of IL-8 secretion Baruch et al., 2011; 
Pearson et al., 2011
L. pneumophila LegK1 Kinase IB NF-B activation Induction of pro-inflammatory 
responses
Ge at al., 2009
Yersinia ssp. YopJ Acetyltransferase MKKs MAPK/ NF-B  
inhibition
Induction of apoptosis/inhibition 
of pro-inflammatory responses
Mukherjee et al.,  
2006
Yersinia ssp. Invasin/YadA Binding 1-integrins FAK activation Actin rearrangements/ 
bacterial uptake
Uliczka et al., 2009
Yersinia ssp. YopH Phosphatase Fyb Fyn inhibition Inhibition of phagocytosis Yuan et al., 2005
Yersinia ssp. YopH Phosphatase FAK/p130Cas FAK inhibition Disruption of focal adhesions/
inhibition of phagocytosis
Black and Bliska, 1997
B. anthracis Anthrax toxin Protease MKKs MAPK inhibition Induction of apoptosis Ali et al., 2011
B. anthracis LF Protease MEK1 MAPK inhibition Induction of apoptosis Park et al., 2002
P. aeruginosa ExoT ADP- 
ribosyltransferase
Crk Crk inhibition Inhibition of invasion Pielage et al., 2008
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in infected cells using one molecule, YopJ (Palmer et al., 1998, 
1999). This 32-kD effector is injected from the pathogen di-
rectly into the host’s cytoplasm through a needle-like complex 
called type III secretion system (T3SS). YopJ (also termed 
YopP) blocks all the MAPK pathways and the NF-B pathway 
by preventing the activation of all MKKs and IKK (but not 
IKK; Fig. 1; Orth et al., 1999). Originally, bioinformatic tools 
identified YopJ as an effector that contained a catalytic domain 
similar to a cysteine protease (Orth et al., 2000). However, bio-
chemical analysis of YopJ revealed that the protein requires an 
intact catalytic triad for its inhibitory acetyltransferase activity; 
a novel posttranslational modification that directly competes 
with phosphorylation. This effector inhibits kinase activation 
by modifying serine and/or threonine residues in the activation 
cofactor, the ribosomal protein S3 (RPS3), for their transcription 
(Wan et al., 2007). RPS3 nuclear translocation is promoted by 
IKK phosphorylation (Wan et al., 2011). The NF-B pathway 
also activates genes involved in the pro-inflammatory response, 
and, possibly more importantly, genes involved in the antiapoptotic 
response (Arsura et al., 1996; Wu et al., 1996). Bacterial pathogens 
have devised a multitude of strategies to interfere with NF-B sig-
naling, often on more than one level, highlighting the importance 
of inhibiting this particular pathway for pathogen survival.
Manipulation of the NF-B pathway
YopJ: an equal opportunity acetyltransferase.  
Yersinia spp. has devised one of the most efficient strategies to 
date to disrupt the innate immune response and promote apoptosis 
Figure 1. Regulation of MAPK and NF-B pathways and their manipulation by bacterial effectors. Bacterial infection triggers PAMP-dependent acti-
vation of PRRs at the host cell membrane. Receptor activation triggers MKKK phosphorylation, which in turn activates MAPK pathways and the NF-B 
pathway via activation of the IKK complex. IKK phosphorylates IB, which then becomes polyubiquitinated and removed by proteasomal degradation. 
Degradation of IB exposes the NLS on NF-B, which subsequently undergoes nuclear translocation and binds to B sites in target promoters to stimulate 
transcription of genes required for pro-inflammatory responses, such as cytokines and chemokines, and genes involved in cell proliferation. Activation 
of NF-B also leads to surface expression of receptors such as CEACAMs, which are hijacked by pathogens to promote their attachment to the host cell 
surface. Some B site-containing promoters require RPS3 as a transcriptional co-factor in addition to NF-B. RPS3 nuclear translocation is dependent on 
its phosphorylation by IKK. Bacterial pathogens manipulate both MAPK and NF-B pathways either by acting as inhibitors (red boxes) or activators 
(green box) of individual components.
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In contrast, the S. flexneri T3SS-injected effector, OspG, 
blocks the cascade further downstream by preventing poly-
ubiquitination and thus degradation of IB, the inhibitor of 
NF-B (Kim et al., 2005). OspG is a protein kinase with an 
unknown phosphorylation target that binds ubiquitinylated E2 
ubiquitin-conjugating enzymes, including the E2 specific for 
IB—UbcH5—and prevents the transfer of ubiquitin onto 
phosphorylated IB by an E3 ubiquitin ligase (Fig. 1). In-
appropriate association of protein domains is a subversive 
mechanism used to redirect signaling systems, and has led to a 
greater understanding of many signaling pathways. Examples 
of this are seen with oncogenic viruses (v-abl), lethal somatic 
chromosomal translocations (Bcr-Abl; Hunter, 2007), bacterial 
extracellular molecules (such as fimbriae), and other pathogenic 
effectors (e.g., EspG).
Modulation of host defenses by extracellular 
scaffolding. Porphyromonas gingivalis, a periopathogen, 
uses proteinaceous extracellular structures—fimbriae (Pierce 
et al., 2009)—to scaffold both the chemokine receptor 4 (CXCR 4) 
and the Toll-like receptor TLR2 on human monocytes together 
in lipid rafts. The crosstalk between CXCR4 and TLR2 re-
sults in elevated levels of cAMP, which acts to stimulate the 
immunomodulatory cAMP-dependent protein kinase A (PKA) 
and induce a negative feedback loop to suppress CXCR4 func-
tion. The authors hypothesize that PKA acts downstream of 
CXCR4 to inhibit TLR2-dependent, NF-B–induced TNF ac-
tivation (inflammatory cytokine), and trigger increased expres-
sion of the immunosuppressive cytokine IL-10. The ultimate 
outcome of this subtle but efficient manipulation of NF-B sig-
naling is diminished production of nitric oxide (NO), which is 
usually generated by macrophages as an inflammatory response 
and secreted as free radicals to fight off pathogens. Suppres-
sion of the inflammatory response and NO secretion results in 
prolonged survival of P. gingivalis (Hajishengallis et al., 2008). 
Thus, the pathogen uses an extracellular scaffolding protein to 
redirect signaling pathways.
Inhibition of the NF-B pathway by EPEC/EHEC 
Nle proteins. The binding affinity of the NF-B p50/p65 
heterodimer to DNA is greatly increased by the NF-B binding 
partner RPS3 (Wan et al., 2007). This regulator of NF-B allows 
specificity in expression of target genes, such as those involved 
in cytokine production and host defense against enterohemor-
rhagic Escherichia coli (EHEC). NleH1 and NleH2 are a pair 
of highly conserved T3SS effectors from both enteropathogenic 
E. coli (EPEC) and EHEC. These effectors contain a conserved 
Ser/Thr kinase domain and a PDZ-binding motif, and are impli-
cated in blocking apoptosis during infection (Fig. 1; Hemrajani 
et al., 2010; Martinez et al., 2010). Both NleH1 and NleH2 are 
also capable of binding RPS3 independent of their kinase activ-
ity (Gao et al., 2009). Binding of EHEC NleH1 to RPS3 inhibits 
RPS3 phosphorylation by IKK, which sequesters RPS3 in the 
cytoplasm and prevents its nuclear translocation, thereby dis-
rupting transcriptional up-regulation of RPS3-dependent genes 
(Gao et al., 2009). The presence of NleH1 leads to increased 
bacterial colonization and diarrhea but, interestingly, decreases 
mortality in a piglet infection model, a paradoxical effect that 
perhaps promotes the spread of the bacteria to other hosts 
loop with an acetyl group from acetyl-CoA, thereby preventing 
their modification by phosphorylation (Orth et al., 1999; Trosky 
et al., 2004; Mittal et al., 2006; Mukherjee et al., 2006; Hao 
et al., 2008). During an infection with Yersinia, host cell signals 
for both survival and apoptosis are normally induced. However, 
with Yersinia strains containing YopJ, the default path will 
always be death because YopJ blocks the survival pathway. 
Using a yeast genetic screen, a conserved site on all MKKs and 
IKK, but not IKK, was revealed to be the docking site for 
YopJ (Hao et al., 2008). As many signaling molecules are con-
served in yeast, this genetically tractable system has become a 
very useful tool to characterize the molecular activity of bacte-
rial effectors. The analysis of YopJ revealed Ser/Thr acetylation 
as a novel posttranslational modification and was one of the first 
examples to highlight the use of competitive posttranslational 
modifications for directing signaling (Mukherjee et al., 2006). 
Additionally, YopJ is an example of a protein that possesses an 
enzymatic activity different from what was predicted through 
bioinformatics, thereby demonstrating the limits of using any 
one tool for studying unknown signaling molecules.
Other homologues of YopJ have been analyzed but their 
targets are less clear. The Salmonella Typhimurium homo-
logue AvrA seems to target different host proteins and play 
multiple roles that vary during the course of infection (Liu 
et al., 2010). For example, early on during infection, it inhib-
its NF-B signaling (Collier-Hyams et al., 2002; Jones et al., 
2008). During later stages of infection, it acetylates MKKs 
such as MKK7 to shut off the JNK pathway, which is acti-
vated early during S. Typhimurium infection (Du and Galán, 
2009). Another YopJ homologue, the effector AopP from the 
fish-pathogen Aeromonas salmonicida, inhibits NF-B signal-
ing using the same catalytic mechanism on another phosphory-
lated target, possibly downstream of IB phosphorylation 
(Fehr et al., 2006).
Binding NEMO: Ubiquitination by Shigella flex-
neri IpaH9.8 blocks NF-B. S. flexneri, an intracellular 
Gram-negative gastrointestinal pathogen capable of causing 
dysentery, blocks the NF-B pathway on several levels to ensure 
silencing of immune responses. Upon invasion of epithelial cells, 
the NF-B cascade would typically be activated when S. flexneri 
lipopolysaccharide binds to the cytoplasmic NLR NOD1, which 
causes enhanced oligomerization of NOD1 and recruitment of 
the serine/threonine kinase receptor-interacting protein 2/RIP-
like interacting CLARP kinase (RIP2/RICK), and NF-B essen-
tial modulator (NEMO), a regulatory subunit of the IKK complex 
(Girardin et al., 2001). However, S. flexneri possesses the effec-
tor IpaH9.8, a protein injected from the pathogen directly into 
the host’s cytoplasm through the T3SS and that possesses E3 
ligase activity for NEMO. IpaH9.8 simultaneously binds NEMO 
and ABIN-1, an ubiquitin-binding adaptor protein, and promotes 
polyubiquitination of NEMO (Fig. 1). Polyubiquitinated NEMO 
undergoes proteolytic degradation, thus inhibiting NEMO- 
dependent activation of the IKK complex (Okuda et al., 2005; 
Rohde et al., 2007; Ashida et al., 2010). Interestingly, inhibition 
by IpaH9.8 is stronger in response to NOD1 than TNF, and fur-
ther study may give insight to how upstream signals bias these 
pathways (Ashida et al., 2010).
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(Gagliardi et al., 2009). CD1 belongs to a family of surface 
glycoproteins, which are expressed on antigen-presenting 
cells (APCs) and are responsible for presenting lipid anti-
gens such as mycobacterial cell wall components to specific 
T cells. Mycobacteria such as Mycobacterium tuberculosis 
and Mycobacterium bovis interact with complement receptor 3 
(CR-3) on the surface of APCs, leading to CR-3–mediated 
phagocytosis (Schlesinger et al., 1990). CR-3 binding results 
in phosphorylation of the MAPK p38, which, in turn, leads 
to phosphorylation of the downstream effector activating tran-
scription factor (ATF-2). Activated ATF-2 is able to bind to 
the CD1A promoter region and decrease CD1 transcription. As 
a result, CD1 expression and surface presentation is reduced. 
Thus, the phagocytosed pathogen’s induction of p38 prevents 
surface display of mycobacterial antigens on APCs by inhibi-
tion of CD1 expression, which might allow mycobacteria to 
evade T cell surveillance during infection in vivo (Gagliardi 
et al., 2009). The manipulation of these signaling pathways 
also results in arrest of phagosome maturation in macrophages 
(Jo et al., 2007) and inhibition of class II MHC expression by 
macrophages (Pennini et al., 2006). These studies highlight a 
mechanism that uses MAPK signaling to reduce T cell recogni-
tion (Gagliardi et al., 2009).
Targeting of MKKs by anthrax toxin. Anthrax 
toxin, secreted by Bacillus anthracis, is another virulence factor 
that can inhibit MAPK signaling. It is a protease that reaches 
the host’s cytoplasm through lipid raft-mediated uptake and 
hydrolyses MKKs (Martchenko et al., 2010; Ali et al., 2011). 
B. anthracis also encodes a toxin called lethal factor (LF) that 
is a metalloproteinase. LF specifically cleaves the N-terminal 
extension of MKKs, resulting in a kinase that can no longer 
interact with its substrate (Duesbery et al., 1998; Vitale et al., 
1998; Park et al., 2002). Importantly, this type of deregulation 
provided insight into the importance of scaffolding a kinase 
with a substrate in the MAPK signaling cascade and a potential 
target for a small molecule LF inhibitor (Joshi et al., 2011; Li 
et al., 2011).
VopA/P: YopJ’s more specific sibling. VopA/P, 
a Vibrio parahaemolyticus effector, is different from its close 
homologue YopJ in that it can inhibit MAPK signaling path-
ways but not the NF-B pathway (Fig. 1). Despite only inhib-
iting MAPK, it has a dual function in which it acetylates not 
only the activation loop of MKKs, thereby inhibiting activation, 
but also acetylates a conserved lysine in the catalytic loop of 
MKKs that is required for coordination of the -phosphate of 
ATP. This modification by VopA/P inhibits the binding of ATP 
(Trosky et al., 2004; Trosky et al., 2007). By analyzing homo-
logues of different effectors, subtle mechanistic differences are 
observed that reveal dramatic differences in host cell responses. 
By inhibiting both NF-B and MAPK pathways, Yersinia YopJ 
will promote apoptosis. In contrast to YopJ, by inhibiting only 
MAPK pathways, V. parahaemolyticus VopA/P permits sur-
vival by allowing activation of the NF-B pathway.
Crosstalk between p38 and JNK revealed by 
OspF. The phosphothreonine lyase OspF, a S. flexneri pro-
tein effector, is translocated into the host cell and localizes 
to the nucleus, where it eliminates a phosphate group from a 
(Wan et al., 2011). Studies of NleH1 have highlighted the 
essentiality of RPS3 phosphorylation by IKK and have shown 
how altering only the specificity of NF-kB through RPS3 in-
hibition compromises defenses and affects cytokine expression 
(Wan et al., 2011)
Another EPEC effector, NleE, blocks NF-B activation 
by inhibition of IKK phosphorylation. The activity of NleE 
is enhanced by a second effector, NleB (Nadler et al., 2010; 
Vossenkämper et al., 2010). Recently, NleC and NleD, mem-
bers of a family of Zn-dependent metalloproteases, were identi-
fied in EPEC. These proteases specifically cleave and inactivate 
RelA (p65), a subunit of NF-B, and JNK, respectively, thus 
blocking NF-B and activator protein 1 (AP-1) activation. The 
net result of the inhibition of NF-B by these bacterial effec-
tors is strong inhibition of the pro-inflammatory cytokine IL-8 
(Baruch et al., 2011; Pearson et al., 2011; Yen et al., 2010).
Activation of the NF-kB pathway by patho-
genic effectors. Listeria monocytogenes has been reported 
to cause local inflammation at the primary site of infection to 
attract monocytes, which they invade and use as a vehicle to 
spread throughout the host and cause systemic infection (Gray 
and Killinger, 1966). Other pathogens induce NF-B activation 
to trigger enhanced surface expression of pathogen receptors on 
host cells. Examples of this include Chlamydophila pneumoniae, 
which causes an NF-B–dependent increase in monocyte 
chemotactic protein 1 (MCP-1) by endothelial cells (Molestina 
et al., 2000) or Neisseria gonorrhoeae, which uses the NF-B 
pathway to up-regulate carcinoembryonic antigen-related cel-
lular adhesion molecules (CEACAMs; Muenzner et al., 2002). 
Further reasons for NF-B activation include permeabilization 
of the vasculature and superficial cell layers to enable patho-
gens to invade deeper tissue layers or the circulatory system, or, 
as in the case of S. Typhimurium, to trigger the reactive oxygen 
species (ROS)-promoted formation of a new respiratory chain, 
which provides the pathogen with a growth advantage over the 
commensal microbiota (Winter et al., 2010).
Some pathogens secrete effector proteins into the host 
specifically to evoke NF-B activation. An example is the Legio-
nella pneumophila type IV secreted effector LegK1, which is a 
Ser/Thr kinase that specifically phosphorylates IB to induce 
its ubiquitination and degradation, allowing NF-B to activate 
downstream pro-inflammatory responses (Fig. 1; Ge et al., 2009). 
Interestingly, LegK1 also appears to have an antiapoptotic ef-
fect. It can be speculated that a wide range of pathogens cause a 
well-timed burst of pro-inflammatory responses upon initial in-
fection to exploit the benefits described earlier, only to switch it 
off at a later stage of infection using specific effector proteins 
that inhibit the NF-B pathway. LegK1 is an IKK mimic that 
does not require phosphorylation of its activation loop and 
thereby is regulated independently of the host signaling ma-
chinery (Ge et al., 2009).
Manipulation of the MAPK pathway
Inhibition of antigen presentation by MAPK activa-
tion. Interference by mycobacteria of MAPK signaling path-
ways by usurping p38 to interfere with CD1 surface expression 
plays a pivotal role in many aspects of immune modulation 
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phosphoinositols with high affinity (Harlan et al., 1994). Akt 
regulates many cellular processes, including cell migration, 
proliferation, survival, and metabolism. Activation of PI3K can 
also activate small GTPases, such as Ras and Rac, which are 
linked to proliferation and cytoskeletal dynamics, respectively 
(Reedijk et al., 1990; Pleiman et al., 1993).
YopH: Terminator of focal adhesion com-
plexes. Upon binding to macrophages, Yersinia spp. disables 
the phagocytosis machinery by introducing YopH, a tyrosine 
phosphatase injected through the T3SS (Rosqvist et al., 1988; 
Guan and Dixon, 1990; Bliska et al., 1991). Using a catalyti-
cally inactive mutant form as a substrate trap, YopH was shown 
to bind p130Cas and FAK, which are both members of the 
focal adhesion complex (Black and Bliska, 1997). YopH ac-
tivity thereby disrupts focal adhesion complexes and inhibits 
phagocytosis, thus limiting the number of internalized bacte-
ria (Mogemark et al., 2005). YopH also dephosphorylates Fyb 
(Fyn-binding protein), an immune cell–specific adaptor protein. 
This disrupts signaling via Fyn and PI3K to small GTPases to 
induce cytoskeletal rearrangements, which are required to initi-
ate the phagocytic process (Yao et al., 1999; Yuan et al., 2005). 
Deletion of YopH severely decreases virulence of the mutant 
strains (Bliska et al., 1991). Thus, YopH targets and destroys 
focal adhesions by dephosphorylating key signaling molecules, 
and highlights the importance of focal adhesions in cell move-
ment and phagocytosis.
Stabilization of the intestinal lining by S. flex-
neri. Enteropathogenic S. flexneri bind to the intestinal mucosal 
layer and invade epithelial cells, where they spread from cell 
to cell to avoid any extracellular steps. This mode of infec-
tion provokes extensive tissue damage and would normally 
lead to shedding of epithelial cells. However, S. flexneri ac-
tively stabilizes the epithelial lining by promoting cell adher-
ence. The T3SS effector OspE localizes to focal adhesion sites, 
where it recruits ILK to promote cell adhesion by inhibiting 
focal adhesion disassembly. Although ILK appears to act as 
a scaffold for OspE localization, mutation of its putative ki-
nase residues leads to a reduction in focal adhesion forma-
tion. Despite the controversies on whether ILK is actually a 
kinase, OspE “activation” of ILK leads to an increase in the 
relative number of focal adhesions, thereby preventing exfolia-
tion of infected mucosal epithelium (Miura et al., 2006; Kim 
et al., 2009). Several other enteropathogens, such as E. coli or 
S. Typhimurium, have been found to possess OspE homologues, 
and it is hypothesized that they use a similar mechanism for 
enhanced ILK recruitment to stabilize the intestinal lining dur-
ing infection to promote bacterial dissemination (Van Nhieu 
and Guignot, 2009).
EspG, a catalytic . . . scaffold? The EHEC T3SS 
effector EspG is another example of how bacteria can manipu-
late the host by “catalytic scaffolding.” Both ADP-ribosylation 
factor (ARF) GTPases and PAKs are substrates of EspG. Arf 
GTPases are mediators of intracellular membrane trafficking 
and organelle remodeling, whereas PAKs are Ser/Thr kinases 
that are activated by Cdc42 and Rac GTPases, thereby regulat-
ing actin remodeling and cellular polarity. EspG inhibits Arf 
GTPase activity by blocking GTPase-activating protein (GAP) 
phosphothreonine residue in the activation loop of the MAPKs 
ERK1/2 and p38 (Fig. 1; Li et al., 2007). This modification 
is irreversible and the kinase can no longer be activated by 
phosphorylation. OspF-catalyzed eliminylation inhibits extra-
cellular signal–regulated kinase (ERK)-mediated activation of 
the mitogen- and stress-activated kinase 1 (MSK1) and MSK2, 
and thus prevents phosphorylation of histone H3, which is 
a prerequisite for chromatin reorganization and presentation 
of B binding sites at NF-B–regulated promoters (Brennan 
and Barford, 2009). The phosphothreonine lyase activity may 
be preferable to phosphatase activity because of the irrevers-
ible nature of the modification. As a consequence, transcrip-
tional up-regulation of genes usually activated by NF-B is 
blocked (Soloaga et al., 2003; Arbibe et al., 2007; Kramer 
et al., 2007). An unexpected side effect of irreversible p38 de-
phosphorylation is that JNK and NF-B activity are actually 
increased, which suggests that inactivation of p38 may reduce 
negative feedback by the upstream activator Tak1, highlight-
ing a layer of crosstalk between the pathways (Reiterer et al., 
2011). Interestingly, at least some of the potential downstream 
effects of JNK and NF-B activation by OspF are silenced, 
as OspF has the concomitant effect of reducing transcription 
of the JNK substrate c-jun, resulting in less phosphorylated 
c-jun and secreted IL-8 (Reiterer et al., 2011). It also reduces 
the accessibility of chromatin to transcription factors, perhaps 
silencing NF-B activation. Silencing these potential drawbacks 
by irreversible deactivation of p38 by inhibiting transcription 
of downstream substrates shows an interesting mechanism that 
prevents a “backfire” result by targeting a central signaling 
pathway like MAPK.
Manipulation of host cytoskeleton and 
membranes by PI3K/Akt, p21-activated 
kinase (PAK), and other kinases
The phosphatidylinositol 3-kinase (PI3K)/Akt kinase signaling 
axis plays an important role in a variety of cellular processes, 
including cytoskeletal dynamics and migration as well as sur-
vival and proliferation (Hannigan et al., 1996; Penuel and Martin, 
1999; Fayard et al., 2010). For this reason, the pathway is 
targeted by many pathogens to reinforce or destroy focal adhe-
sions, which play an integral role in phagocytosis. The PI3K 
pathway can be triggered by activation of receptor tyrosine 
 kinases or ligand binding to integrins, both leading to phosphory-
lation of downstream kinase targets (Fig. 2). Receptor activation 
leads to recruitment and activation of focal adhesion kinase 
(FAK) or integrin-linked kinase (ILK). These, in turn, recruit 
cytoplasmic components of the receptor-linked signaling com-
plex, including the tyrosine kinase Src, the adapter protein Crk, 
and p130Cas (Crk-associated substrate). Crk phosphorylation 
leads to strong activation of the small GTPase Rac, which is re-
quired for cell motility. Src phosphorylation triggers the associ-
ation of PI3K with the signaling complex. PI3K phosphorylates 
phosphoinositols at the D3 position and, depending on the sub-
strate, generates either PI(3)P, PI(3,4)P2, or PI(3,4,5)P3. Gener-
ation of PI(3,4)P2 or PI(3,4,5)P3 recruits the Ser/Thr kinase Akt 
(also known as protein kinase B or PKB) to the membrane via 
its pleckstrin homology (PH) domain, which binds to these 
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after pathogen internalization by inhibiting pathogen-induced 
Abl-dependent Crk phosphorylation, presumably to block fur-
ther invasion (Pielage et al., 2008). Internalization studies with 
P. aeruginosa demonstrated that the phagocytic nature of S2 cells 
make them ideal for use in identification of host molecules im-
portant for bacterial internalization using RNAi-mediated gene 
inactivation (Pielage et al., 2008). Their studies uncovered the 
diversity of host molecules required for successful invasion by 
intracellular bacteria.
P. aeruginosa also provides an interesting example 
of how the PI3K pathway can be exploited to promote bacterial 
tissue invasion. P. aeruginosa preferably attaches to and invades 
epithelial cell layers from the basolateral side. To gain entry 
from the exposed apical surface, it subverts the PI3K pathway 
by binding to an unknown receptor present in tight junctions, 
which recruits and activates PI3K. This triggers the generation 
of PIP3 at the apical membrane and recruitment of Akt, which 
in turn redirects trafficking of basolateral membrane compo-
nents to the apical side by transcytosis. Consequently, PIP3-rich 
membrane protrusions form on the apical side and facilitate 
P. aeruginosa attachment and entry into the epithelial cell layer 
(Kierbel et al., 2007). Studies on this pathogen have thus revealed 
several points of crosstalk between kinase pathways and signal-
ing cascades mediating either cytoskeletal dynamics or membrane 
trafficking, all exploited to achieve entry of P. aeruginosa into 
host cells. These studies also highlight the importance of cell 
binding and thus GTP hydrolysis, while at the same time act-
ing as an allosteric activator of PAK. Both Arf and PAK 
interact with EspG simultaneously by binding to different 
surfaces of the effector protein. By recruiting and inactivat-
ing Arf, EspG localizes PAK activity to specific membrane 
compartments, thereby reprogramming processes such as 
cellular polarity, receptor trafficking, and protein secretion 
to the pathogen’s advantage (Germane and Spiller, 2011; 
Selyunin et al., 2011). The study of this pathogenic effector 
has provided insight into host mechanisms involved in intra-
cellular trafficking.
The complex nature of Pseudomonas aerugi-
nosa internalization. P. aeruginosa is another example of 
a pathogen taking advantage of the interplay between kinase 
and GTPase signaling pathways to manipulate the cytoskeletal 
machinery and promote its own internalization. Recent studies 
with P. aeruginosa have revealed the potential interplay of 
several cytoskeleton-associated GTPases and kinases. Pielage 
et al. (2008) used an RNAi screen of Drosophila S2 cells to 
identify host factors required for P. aeruginosa invasion. 
The screen identified Abl tyrosine kinase, the adaptor protein 
Crk, the GTPases Rac1 and Cdc42, as well as PAK as compo-
nents of a host signaling pathway leading to internalization 
of P. aeruginosa, and the pathways were subsequently vali-
dated by different complementary approaches. Interestingly, the 
P. aeruginosa T3SS effector ExoT takes control of the pathway 
Figure 2. Host signaling pathways exploited for bacterial invasion and colonization. Ligand-activated transmembrane receptors (integrins or receptor 
tyrosine kinases) recruit the cytoplasmic signaling proteins FAK or ILK. This in turn leads to binding of p130Cas and Crk, as well as Src and PI3K. PI3K 
converts PIP2 to PIP3, which binds the pleckstrin homology (PH) domain of Akt. Akt mediates host survival and proliferation signaling. PIP3 also recruits 
Rho GTPases to the membrane, where they activate actin rearrangements that lead to cellular motility or bacterial uptake through formation of membrane 
protrusions. Rho GTPases are also activated by Crk. P. aeruginosa activates PI3K signaling by integrin or RTK binding to promote cellular uptake. The 
S. flexneri T3SS-injected effector OspE activates PI3K signaling by recruiting ILK. Yersinia spp. and P. aeruginosa inject T3SS effectors YopH and ExoT 
to inhibit GTPase activation and phagocytosis (Yersinia spp.) or stop invasion at a later stage of infection (P. aeruginosa). Direct manipulation of small 
GTPases is a major target for a variety of bacterial effectors (Aktories et al., 2000; Alto, 2008).
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polarity in dictating invasion, as it creates a suitable PIP3-rich 
microenvironment at the apical surface to allow bacterial entry 
into the host cell (Kierbel et al., 2007).
Conclusion
Studying the mechanisms of virulence that pathogens use to 
propagate in a host not only provides potential targets for treat-
ment, but also often provides insight into the host molecules 
affected. Although some of the future benefits of knowledge 
gained about eukaryotic signaling may be elusive at this point, 
the potential for discovery is obvious. The complex and central 
kinase pathways outlined in this review highlight the impor-
tance of using novel angles of investigation. Seeing signaling 
pathways through the lens of a pathogen reveals unknown intri-
cacies of kinase-mediated signaling pathways.
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